JPH08183726A - Skin preparation for external use - Google Patents

Skin preparation for external use

Info

Publication number
JPH08183726A
JPH08183726A JP6339448A JP33944894A JPH08183726A JP H08183726 A JPH08183726 A JP H08183726A JP 6339448 A JP6339448 A JP 6339448A JP 33944894 A JP33944894 A JP 33944894A JP H08183726 A JPH08183726 A JP H08183726A
Authority
JP
Japan
Prior art keywords
weight
phospholipid
hydrogenated
skin
external preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6339448A
Other languages
Japanese (ja)
Other versions
JP3521517B2 (en
Inventor
Mariko Asai
真理子 浅井
Hisami Kameyama
久美 亀山
Noboru Naito
昇 内藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kose Corp
Original Assignee
Kose Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kose Corp filed Critical Kose Corp
Priority to JP33944894A priority Critical patent/JP3521517B2/en
Publication of JPH08183726A publication Critical patent/JPH08183726A/en
Application granted granted Critical
Publication of JP3521517B2 publication Critical patent/JP3521517B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PURPOSE: To obtain a skin preparation for the external use, having remarkably excellent humectant effect beautifying and antioxidizing effects. CONSTITUTION: The skin preparation for the external use comprises a liposome- containing aqueous dispersion containing (a) 0.1-5wt.% of a phospholipid and (b) 0.1-5wt.% of cholesterol and/or 5-40wt.% of 1,3-butylene glycol at a (a)/(b) ratio of 1/0.1 to 1/1, and a humectant, a beautifying agent and an antioxidizing agent.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、皮膚外用剤に関し、更
に詳細には、特定成分より構成されたリポソーム含有水
分散液と保湿剤、美白剤、抗酸化剤とを含有することを
特徴とする保湿、美白及び抗酸化効果が顕著に良好な皮
膚外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin external preparation, and more specifically, it contains a liposome-containing aqueous dispersion composed of specific components, a moisturizing agent, a whitening agent, and an antioxidant. The present invention relates to an external preparation for skin which has remarkably good moisturizing, whitening and antioxidant effects.

【0002】[0002]

【従来の技術】生体膜の主要構成成分であるリン脂質の
二分子膜からなる閉鎖小胞であるリポソームは、生体膜
モデルとして研究に用いられるとともに、古くから薬剤
のマイクロカプセルとして医薬品や化粧品への利用が試
みられていた。特に、化粧料分野においては、マイクロ
カプセルとして価値のある形態であること、リポソーム
の構成成分であるリン脂質そのものが生体膜由来の安全
性の高い両親媒性物質であること等から、注目を集めて
いた。
2. Description of the Related Art Liposomes, which are closed vesicles composed of bilayer membranes of phospholipids, which are the main constituents of biological membranes, have been used for research as a model of biological membranes, and have long been used as microcapsules for pharmaceuticals and cosmetics. Was being attempted. In the cosmetics field, in particular, it has attracted attention because it has a valuable form as a microcapsule, and the phospholipid itself, which is a constituent component of the liposome, is a highly safe amphipathic substance derived from a biological membrane. Was there.

【0003】[0003]

【発明が解決しようとする課題】このリポソームを化粧
料に応用することのみならず、更にその機能を高め、従
来にない顕著な効果を有する化粧料及び皮膚外用剤の開
発が急務とされていた。
There has been an urgent need to develop not only the application of these liposomes to cosmetics but also the function of the liposomes, and the cosmetics and external preparations for skin having remarkable effects which have never been obtained. .

【0004】[0004]

【課題を解決するための手段】本発明者らは鋭意研究の
結果、特定成分から構成されるリポソーム含有水分散液
と保湿剤、美白剤、抗酸化剤とを含有することにより、
各々の効果が飛躍的に向上する皮膚外用剤が得られるこ
とを見いだし、本発明を完成するに至った。すなわち、
本発明は、(a)リン脂質 0.1〜5重量%、(b)
コレステロール及び/又はその誘導体 0.1〜5重量
%、(c)グリセリン及び/又は1,3−ブチレングリ
コール 5〜40重量%を含有し、かつ、(a):
(b)が1:0.1〜1:1であるリポソーム含有水分
散液と、特定の保湿剤、美白剤、抗酸化剤とを含有する
ことを特徴とする皮膚外用剤である。
Means for Solving the Problems As a result of earnest research, the present inventors have found that a liposome-containing aqueous dispersion composed of specific components, a moisturizing agent, a whitening agent, and an antioxidant are contained.
The inventors have found that an external preparation for skin in which the respective effects are dramatically improved can be obtained, and completed the present invention. That is,
The present invention provides (a) phospholipids 0.1 to 5% by weight, (b)
0.1 to 5% by weight of cholesterol and / or a derivative thereof, (c) glycerin and / or 5 to 40% by weight of 1,3-butylene glycol, and (a):
A skin external preparation characterized in that (b) contains a liposome-containing aqueous dispersion having a ratio of 1: 0.1 to 1: 1 and a specific moisturizing agent, whitening agent, and antioxidant.

【0005】本発明で用いられる(a)成分のリン脂質
としては、例えば、ホスファチジルコリン、ホスファチ
ジルエタノールアミン、ホスファチジルセリン、ホスフ
ァチジルイノシトール、リゾホスファチジルコリン、ス
フィンゴミエリン、卵黄レシチン、大豆レシチン等の天
然リン脂質、ジオレオイルホスファチジルコリンなどの
合成リン脂質、または天然由来のリン脂質の不飽和炭素
鎖を水素により飽和とした水素添加リン脂質、その他大
腸菌等の微生物から抽出されるリン脂質等が挙げられ、
これらを一種又は二種以上組み合わせて使用することが
できる。
Examples of the phospholipid of the component (a) used in the present invention include natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, lysophosphatidylcholine, sphingomyelin, egg yolk lecithin and soybean lecithin; Synthetic phospholipids such as oleoylphosphatidylcholine, or hydrogenated phospholipids obtained by saturating unsaturated carbon chains of naturally-derived phospholipids with hydrogen, and other phospholipids extracted from microorganisms such as Escherichia coli.
These can be used alone or in combination of two or more.

【0006】この中で、水素添加大豆リン脂質、水素添
加卵黄リン脂質、水素添加ホスファチジルコリン、水素
添加ホスファチジルセリンから選ばれる一種又は二種以
上が好ましく、配合量は0.1〜5重量%(以下、単に
「%」で示す)である。0.1%よりも少ないとリポソ
ームの生成率が低くなり、また、5%を超えて配合する
とゲル化してしまい好ましくない。
Among these, one or more selected from hydrogenated soybean phospholipid, hydrogenated egg yolk phospholipid, hydrogenated phosphatidylcholine and hydrogenated phosphatidylserine are preferable, and the compounding amount is 0.1 to 5% by weight (hereinafter , Simply indicated by "%"). If it is less than 0.1%, the liposome production rate will be low, and if it exceeds 5%, gelation will occur, which is not preferable.

【0007】(b)成分のコレステロール及び/又はそ
の誘導体としては、例えば、コレステロール、コレステ
リルステアレート、コレステリルパルミテート等が挙げ
られ、これらを一種又は二種以上組み合わせて使用する
ことができる。
Examples of the cholesterol and / or its derivative as the component (b) include cholesterol, cholesteryl stearate, cholesteryl palmitate and the like, and these can be used alone or in combination of two or more kinds.

【0008】配合量は、0.1〜5%が好ましく、0.
1%よりも少ないとリポソームの安定性が悪くなり、ま
た、5%を超えて配合すると経時的に(b)成分の沈澱
が析出してしまう。
The blending amount is preferably 0.1 to 5%,
If it is less than 1%, the stability of the liposome will be poor, and if it exceeds 5%, the component (b) will precipitate over time.

【0009】(c)成分のグリセリン及び/又は1,3
−ブチレングリコールの配合量は5〜40%である。5
%よりも少ないとリポソームの分散性や安定性が悪くな
り、また、40%を超えて配合するとべたつきを生じる
ため、官能特性上好ましくない。
Component (c) glycerin and / or 1,3
The amount of butylene glycol is 5-40%. 5
If it is less than 40%, the dispersibility and stability of the liposome will be poor, and if it exceeds 40%, stickiness will occur, which is not preferable in terms of sensory properties.

【0010】さらに、上記(a)成分と(b)成分の重
量比が、(a):(b)=1:0.1〜1:1であるこ
とを必須とする。この範囲内であると安定性の良好なリ
ポソーム含有水分散液を得ることができる。
Further, it is essential that the weight ratio of the component (a) to the component (b) is (a) :( b) = 1: 0.1 to 1: 1. Within this range, a liposome-containing aqueous dispersion having good stability can be obtained.

【0011】本発明において、上記成分を含有するリポ
ソーム含有水分散液は、通常知られている方法、例え
ば、ボルテクスイング法(A.D.Bangham、
J.Mol.Biol.,13,238(196
5))、ソニケーション法(C.Huang,Bioc
hem.,8,344(1969))、プレベシクル法
(H.Trauble,Neurosci.Res.P
rog.Bull.,9,273(1971))、エタ
ノール注入法(S.Batzri,Biochem.B
iophys.Acta.,298,1015(197
3))、フレンチプレス押出法(Y.Barenhol
z,FEBS Lett.,99,210(197
9))、コール酸除去法(Y.Kagawa,J.Bi
ol.Chem.,246,5477(1971))、
トリトンX−100バッチ法(W.J.Gerrits
en,Eur.J.Biochem.,85,255
(1978))、Ca2+融合法(D.Papahado
jopoulos,Biochem.Biophys.
Acta.,394,483(1975))、エーテル
注入法(D.Deazer,Biochem.Biop
hys.Acta.,443,629(1976))、
アニーリング法(R.Lawaczeck,Bioch
em.Biophys.Acta.,443,313
(1976))、凍結融解融合法(M.Kasahar
a,J.Biol.Chem.,252,7384(1
977))、W/O/Wエマルジョン法(S.Mats
umoto,J.Colloid Interface
Sci.,62,149(1977))、逆相蒸発法
(F.Szoka,Proc.Natl.Acad.S
ci.USA,75,4194(1978))、多価ア
ルコール法(特開昭60−7932号)等により調製す
ることができる。
In the present invention, the liposome-containing aqueous dispersion containing the above components is prepared by a generally known method, for example, the vortexing method (AD Bangham,
J. Mol. Biol. , 13, 238 (196
5)), sonication method (C. Huang, Bioc
hem. , 8, 344 (1969)), a pre-vesicle method (H. Trauble, Neurosci. Res. P.
log. Bull. , 9, 273 (1971)), ethanol injection method (S. Batzri, Biochem. B.
iophys. Acta. , 298, 1015 (197)
3)), French press extrusion method (Y. Barenhol
z, FEBS Lett. , 99, 210 (197
9)), cholic acid removal method (Y. Kawagawa, J. Bi.
ol. Chem. , 246, 5477 (1971)),
Triton X-100 Batch Method (WJ Gerrits
en, Eur. J. Biochem. , 85, 255
(1978)), Ca 2+ fusion method (D. Papahado
jopoulos, Biochem. Biophys.
Acta. , 394, 483 (1975)), an ether injection method (D. Deazer, Biochem. Biop.
hys. Acta. , 443, 629 (1976)),
Annealing method (R. Lawaczeck, Bioch
em. Biophys. Acta. , 443, 313
(1976)), a freeze-thaw fusion method (M. Kasahar.
a, J. Biol. Chem. , 252, 7384 (1
977)), W / O / W emulsion method (S. Mats
umoto, J .; Colloid Interface
Sci. , 62, 149 (1977)), reverse phase evaporation method (F. Szoka, Proc. Natl. Acad. S.
ci. USA, 75, 4194 (1978)), polyhydric alcohol method (JP-A-60-7932) and the like.

【0012】本発明品の皮膚外用剤に対する上記リポソ
ーム含有水分散液の配合量は特に限定されないが、好ま
しくは、1.0〜90%である。さらに、後述する保湿
剤、美白剤並びに抗酸化剤とを併用することにより、本
発明品の皮膚外用剤を得ることができる。
The amount of the above liposome-containing aqueous dispersion compounded in the external preparation for skin of the present invention is not particularly limited, but is preferably 1.0 to 90%. Furthermore, the external preparation for skin of the present invention can be obtained by using together with a moisturizing agent, a whitening agent and an antioxidant described later.

【0013】保湿剤としては、ヒアルロン酸、コラーゲ
ン、エラスチンから選ばれる一種又は二種以上を適宜選
択して配合することができる。保湿剤の配合量は特に限
定されないが、好ましくは0.001〜5%である。こ
の範囲で用いれば、本発明品の保湿効果がより顕著なも
のとなる。
As the humectant, one kind or two or more kinds selected from hyaluronic acid, collagen and elastin can be appropriately selected and blended. The blending amount of the moisturizer is not particularly limited, but is preferably 0.001 to 5%. When used in this range, the moisturizing effect of the product of the present invention becomes more remarkable.

【0014】美白剤としては、プラセンタエキス、アス
コルビン酸及びその誘導体から選ばれる一種又は二種以
上を適宜選択して配合することができる。アスコルビン
酸誘導体としては、例えば、リン酸L−アスコルビルマ
グネシウム、L−アスコルビン酸硫酸エステル二ナトリ
ウム、ジパルミチン酸アスコルビル等が挙げられる。美
白剤の配合量は特に限定されないが、好ましくは0.0
01〜5%である。この範囲で用いれば、本発明品の美
白効果がより顕著なものとなる。
As the whitening agent, one or more selected from placenta extract, ascorbic acid and its derivatives can be appropriately selected and blended. Examples of the ascorbic acid derivative include L-ascorbyl magnesium phosphate, disodium L-ascorbate sulfate, and ascorbyl dipalmitate. The amount of the whitening agent is not particularly limited, but is preferably 0.0
It is 01 to 5%. When used in this range, the whitening effect of the product of the present invention becomes more remarkable.

【0015】抗酸化剤としては、ラクトフェリン、麦芽
根抽出物、モッカ抽出物から選ばれる一種又は二種以上
を適宜選択して配合することができる。抗酸化剤の配合
量は特に限定されないが、好ましくは乾燥固形分として
0.0001〜5%である。この範囲で用いれば、本発
明品の抗酸化効果がより顕著なものとなる。
As the antioxidant, one or more selected from lactoferrin, malt root extract and mocca extract can be appropriately selected and blended. The blending amount of the antioxidant is not particularly limited, but the dry solid content is preferably 0.0001 to 5%. When used in this range, the antioxidant effect of the product of the present invention becomes more remarkable.

【0016】上記の保湿剤、美白剤並びに抗酸化剤は天
然由来、微生物由来及び化学合成品のいずれをも使用す
ることができ、また、天然由来の場合の抽出方法及び精
製処理方法等についても特に限定されない。
The above moisturizers, whitening agents and antioxidants may be of natural origin, microbial origin or chemically synthesized products, and in the case of natural origin, extraction method and purification treatment method, etc. There is no particular limitation.

【0017】本発明品の皮膚外用剤は、上記の保湿剤、
美白剤、抗酸化剤を前述したリポソーム含有水分散液に
配合することによって得られるが、調製方法としては、
調製したリポソーム含有水分散液に添加混合しても、ま
た、リポソーム含有水溶液調製時に予め添加しても良
い。
The external preparation for skin of the present invention is a moisturizer as described above,
It can be obtained by blending a whitening agent and an antioxidant with the liposome-containing aqueous dispersion described above.
It may be added to and mixed with the prepared liposome-containing aqueous dispersion, or may be added in advance when preparing the liposome-containing aqueous solution.

【0018】本発明品の皮膚外用剤は、上記必須成分の
他に、皮膚外用剤や化粧料に配合される成分、例えば、
油剤、界面活性剤、粉体、顔料、染料、水溶性高分子、
紫外線吸収剤、防腐剤、香料等を本発明の効果を損なわ
ない範囲で配合することができる。
The external preparation for skin of the present invention comprises, in addition to the above-mentioned essential components, components to be added to the external preparation for skin and cosmetics, for example,
Oil agent, surfactant, powder, pigment, dye, water-soluble polymer,
An ultraviolet absorber, an antiseptic, a fragrance and the like can be added within a range not impairing the effects of the present invention.

【0019】[0019]

【実施例】次に、実施例を挙げて本発明をさらに詳細に
説明するが、本発明はこれら実施例に限定されるもので
はない。
EXAMPLES Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.

【0020】製造例1〜3及び比較製造例4〜6 リポ
ソーム含有水分散液 下記表1に示す組成のリポソーム含有水分散液を製造し
た。
Production Examples 1 to 3 and Comparative Production Examples 4 to 6 Liposome-containing aqueous dispersions A liposome-containing aqueous dispersion having the composition shown in Table 1 below was produced.

【0021】[0021]

【表1】 [Table 1]

【0022】(製造方法) A:成分1〜3を成分6の一部で水和した後、成分6の
残部に分散する。 B:Aをマイクロフルイダイザーにて処理する。 C:Bに成分4、5を添加し、リポソーム含有水分散液
を得る。
(Production Method) A: Components 1 to 3 are hydrated with a part of the component 6, and then dispersed in the rest of the component 6. B: A is processed with a microfluidizer. C: Components 4 and 5 are added to B to obtain a liposome-containing aqueous dispersion.

【0023】上記のように得られたリポソーム含有水分
散液を透過型電子顕微鏡にて観察したところ、本発明に
係わる製造例1〜3は、比較製造例4〜6に比べて良好
なリポソーム形態を有し、安定性も良好であった。
When the aqueous dispersion containing liposomes obtained as described above was observed with a transmission electron microscope, Production Examples 1 to 3 according to the present invention showed better liposome morphology than Comparative Production Examples 4 to 6. And stability was also good.

【0024】実施例1〜4及び比較例1〜5 乳液 下記表2に示す組成の乳液を製造し、その保湿効果を評
価した。保湿効果の評価は、角質水分量の測定及び落屑
改善効果の測定により行った。
Examples 1 to 4 and Comparative Examples 1 to 5 Emulsion An emulsion having the composition shown in Table 2 below was produced, and its moisturizing effect was evaluated. The moisturizing effect was evaluated by measuring the amount of keratin water content and the effect of improving desquamation.

【0025】[0025]

【表2】 [Table 2]

【0026】(製造方法) A:成分1〜5を加熱混合し、70℃とする。 B:成分6〜11及び15を加熱混合し、70℃とす
る。 C:AにBを加えて乳化混合し、成分12を添加した後
冷却して成分13、14を加え、均一に混合して乳液を
得た。
(Production Method) A: Components 1 to 5 are heated and mixed to 70 ° C. B: Components 6 to 11 and 15 are heated and mixed to 70 ° C. C: B was added to A and emulsified and mixed, component 12 was added and then cooled, components 13 and 14 were added, and uniformly mixed to obtain an emulsion.

【0027】1.角質水分量の測定 被験部位(前腕)において、左右対称に同程度の肌荒れ
が認められるパネル54名(22〜54才:各被験乳液
6名)を対象とした。被験乳液の適量を毎日朝夕2回被
験部位の左側に塗布し、また、右側は塗布せず対照とし
て、4週間継続使用後、表皮角質水分量測定装置SKI
CON−200(アイ・ビイ・エス社製)にて左右の水
分量を測定した。次式より各パネルの角質水分増加率を
算出し、それを平均化した。
1. Measurement of water content of keratin 54 panels (22 to 54 years old: 6 milk emulsions of each test) in which bilaterally symmetrical rough skin was observed in the test site (forearm) were targeted. An appropriate amount of the test emulsion was applied to the left side of the test site twice daily in the morning and evening, and the right side was not applied, and was used as a control for 4 weeks continuously.
The left and right water contents were measured with CON-200 (manufactured by IBS). The rate of increase in keratin water content of each panel was calculated from the following formula and averaged.

【0028】[0028]

【化1】 Embedded image

【0029】2.落屑改善効果 被験部位(下腿伸側)において、左右対照に同程度の落
屑が認められるパネル54名(22〜54才:各被験乳
液6名)を対象とした。被験乳液の適量を毎日朝夕2回
被験部位の左側に塗布し、また、右側は塗布せず対照と
して、4週間継続使用後、被験部位を観察し、対照と比
較した塗布部の落屑改善効果を以下の基準で評価した。 (評価基準) 有 効:落屑が明らかに目立たなくなった。 やや有効:落屑があまり目立たなくなった。 無 効:変わらない。 上記評価結果を表3に示す。
2. Scalping improvement effect 54 panelists (22 to 54 years old: 6 test milk emulsions each) were found to have similar scaling in the left and right controls at the test site (extension side of the lower leg). Appropriate amount of test emulsion was applied to the left side of the test site twice daily in the morning and evening, and the right side was not applied as a control, and after 4 weeks of continuous use, the test site was observed and the effect of improving desquamation of the applied part compared to the control was observed. The following criteria were evaluated. (Evaluation Criteria) Effective: Desquamation is clearly inconspicuous. Slightly effective: Scaling became less noticeable. Ineffective: No change. The evaluation results are shown in Table 3.

【0030】[0030]

【表3】 [Table 3]

【0031】上記結果から明らかなように、本発明に係
わる乳液は、角質水分保持効果及び落屑改善効果に優
れ、顕著な保湿効果を有するものであり、肌荒れ改善に
対して極めて有効であった。
As is clear from the above results, the emulsion according to the present invention has an excellent effect of retaining keratin water and an effect of improving desquamation, has a remarkable moisturizing effect, and is extremely effective in improving rough skin.

【0032】実施例5〜8及び比較例6〜9 クリーム 下記表4に示す組成のクリームを製造し、その美白効果
を評価した。評価方法については以下に示す。
Examples 5 to 8 and Comparative Examples 6 to 9 Creams Creams having the compositions shown in Table 4 below were produced and their whitening effect was evaluated. The evaluation method is shown below.

【0033】[0033]

【表4】 [Table 4]

【0034】(製造方法) A:成分1〜7を加熱混合し、70℃とする。 B:成分8〜11及び14を加熱混合し、70℃とす
る。 C:AにBを加えて乳化混合した後、冷却して成分1
2、13を加え均一に混合してクリームを得た。
(Manufacturing Method) A: Components 1 to 7 are mixed by heating to 70 ° C. B: Components 8 to 11 and 14 are heated and mixed to 70 ° C. C: B was added to A, and the mixture was emulsified and mixed, followed by cooling and the component 1
2 and 13 were added and mixed uniformly to obtain a cream.

【0035】1.美白効果(A) 有色モルモットの背部を剃毛し、紫外線を照射すると色
素沈着を生じることを利用して、被験クリームの美白効
果を検討した。被験クリーム1品につき10匹の有色モ
ルモットを用いて、紫外線照射の24時間前と照射直後
及び照射24時間後に、モルモット背部の4カ所(2×
2cm)に、被験クリームを0.2mlずつよく擦り込
み、照射した。但し、照射の前には塗布部位を温水でよ
く洗浄した。紫外線照射は、FL20S・BLBランプ
とFL20S・E30ランプ(各々、東芝社製)を用い
て、各3本ずつ同時に照射し、紫外線量は、4.8×1
6erg/cm2とした。照射の7日後に各部位を観察
し、以下の基準で色素沈着及び美白効果を評価した。
1. Whitening Effect (A) The whitening effect of the test cream was examined by utilizing the fact that the back of colored guinea pigs was shaved and ultraviolet rays were irradiated to cause pigmentation. Ten colored guinea pigs were used for each cream to be tested, and at four points (2 × 2 ×) on the back of the guinea pig 24 hours before, immediately after, and 24 hours after the ultraviolet irradiation.
2 cm) was thoroughly rubbed with 0.2 ml of the test cream and irradiated. However, the application site was thoroughly washed with warm water before irradiation. For the UV irradiation, FL20S / BLB lamps and FL20S / E30 lamps (each manufactured by Toshiba Corp.) were used to irradiate three of each at the same time, and the UV amount was 4.8 × 1.
It was set to 0 6 erg / cm 2 . Each site was observed 7 days after irradiation, and the pigmentation and whitening effect were evaluated according to the following criteria.

【0036】(色素沈着評点) 0:色素沈着が全く認められない。 1:ごくわずか色素沈着が認められる。 2:色素沈着が認められるが、非照射部位との境界は不
明瞭。 3:色素沈着が認められ、非照射部位との境界が鮮明で
ある。
(Pigmentation Rating) 0: No pigmentation is observed. 1: Very slight pigmentation is observed. 2: Pigmentation is observed, but the boundary with the non-irradiated site is unclear. 3: Pigmentation was observed, and the boundary with the non-irradiated site was clear.

【0037】(美白効果) 色素沈着評点が1点以下のモルモットが10匹中 8匹以上 :著効 6匹以上8匹未満:有効 4匹以上6匹以下:やや有効 3匹以下 :無効(Whitening Effect) Guinea pigs with a pigmentation score of 1 point or less 8 out of 10: excellent effect 6 to less than 8 animals: effective 4 to 6 animals: slightly effective 3 or less: ineffective

【0038】2.美白効果(B) 23〜44才の女性15名をパネルとし、毎日、朝と昼
の2回、洗顔後に被験クリームを、各人2品づつそれぞ
れ適量顔面に6週間にわたって塗布することにより使用
テストを行い、以下の基準で評価した。 (評価基準) 有 効:シミ、ソバカスが目立たなくなった。 やや有効:シミ、ソバカスがあまり目立たなくなった。 無 効:変わらない。 上記各評価結果を表5に示す。
2. Whitening effect (B) 15 women aged 23 to 44 years were used as a panel, and a test cream was applied twice a day, twice a day, morning and noon, to each person for two weeks, and an appropriate amount of the test cream was applied to the face for 6 weeks. The evaluation was performed according to the following criteria. (Evaluation Criteria) Effective: Spots and freckles disappeared. Slightly effective: Spots and freckles are less noticeable. Ineffective: No change. Table 5 shows the evaluation results.

【0039】[0039]

【表5】 [Table 5]

【0040】上記結果から明らかなように、本発明に係
わるクリームは、色素沈着抑制効果を有し、美白効果に
も優れるものであった。
As is clear from the above results, the cream according to the present invention had an effect of suppressing pigmentation and an excellent whitening effect.

【0041】実施例9〜12及び比較例10〜13 ク
リーム 下記表6に示す組成のクリームを製造して、過酸化脂質
濃度を測定し、さらに美肌効果及び皮膚老化防止効果に
ついて評価した。
Examples 9 to 12 and Comparative Examples 10 to 13 Creams Creams having the compositions shown in Table 6 below were produced, the lipid peroxide concentration was measured, and the skin beautifying effect and the skin aging preventing effect were evaluated.

【0042】[0042]

【表6】 [Table 6]

【0043】(製造方法) A:成分1〜7を加熱混合し、70℃とする。 B:成分8〜12及び15を加熱混合し、70℃とす
る。 C:AにBを加えて乳化混合し、冷却後、成分13、1
4を加えて均一に混合してクリームを得た。
(Manufacturing Method) A: Components 1 to 7 are mixed by heating to 70 ° C. B: Components 8 to 12 and 15 are mixed by heating to 70 ° C. C: B is added to A, emulsified and mixed, and after cooling, components 13 and 1
4 was added and mixed uniformly to obtain a cream.

【0044】1.過酸化脂質濃度の測定 上記のように得られたクリームを40℃の恒温槽にて4
週間保存した後、精製水で1%に希釈したものを試料溶
液とした。試薬として、トリクロロ酢酸15g、チオバ
ルビツール酸0.375g、1N塩酸25ml及びブチ
ルヒドロキシアニソールを2%含有するエタノール溶液
3mlに、精製水を加えて100mlとしたもの(以
下、TBA試薬という)を用いた。試料溶液1mlを試
験管に取り、これに上述のTBA試薬2mlを加えて混
合し、試験管を密閉して95℃にて15分間加熱後、速
やかに室温まで冷却した。そして、2500rpmにて
10分間遠心分離した後、上澄み液を取り、535nm
の吸光度を測定した。標準溶液として、1,1,3,3
−テトラエトキシプロパン溶液を用い、同様の操作を行
い検量線を作成して、この検量線より過酸化脂質濃度を
求めた。
1. Measurement of Lipid Peroxide Concentration The cream obtained as described above was placed in a constant temperature bath at 40 ° C for 4 hours.
After being stored for a week, it was diluted to 1% with purified water to obtain a sample solution. As a reagent, use trichloroacetic acid 15 g, thiobarbituric acid 0.375 g, 1N hydrochloric acid 25 ml and ethanol solution 3 ml containing 2% of butylhydroxyanisole to make 100 ml by adding purified water (hereinafter referred to as TBA reagent). I was there. 1 ml of the sample solution was taken in a test tube, 2 ml of the above-mentioned TBA reagent was added to and mixed with the test tube, the test tube was sealed, heated at 95 ° C. for 15 minutes, and then rapidly cooled to room temperature. Then, after centrifuging at 2500 rpm for 10 minutes, the supernatant liquid is collected and 535 nm
The absorbance of was measured. As a standard solution, 1, 1, 3, 3
-Using tetraethoxypropane solution, the same operation was performed to prepare a calibration curve, and the lipid peroxide concentration was determined from this calibration curve.

【0045】2.美肌及び皮膚老化防止効果 28〜58才の女性評価パネル15名により、各人2品
づつ毎日、朝と昼の2回、6週間にわたって洗顔後に被
験クリームの適量を顔面に塗布した際の肌状態を観察し
た。塗布による美肌及び皮膚老化防止効果を以下の基準
によって評価した。
2. Beautiful skin and skin aging prevention effect 15 female evaluation panels aged 28 to 58, 2 products for each person, twice daily in the morning and noon twice, for 6 weeks, after washing for 6 weeks, an appropriate amount of the test cream was applied to the face. Was observed. The following criteria evaluated the beautiful skin and the skin aging prevention effect by application.

【0046】 〈美肌効果〉 (評価) (内容) 有 効:肌のくすみが目立たなくなった。 やや有効:肌のくすみがあまり目立たなくなった。 無 効:使用前と変化なし。 〈皮膚老化防止効果〉 (評価) (内容) 有 効:肌のはり、つやが改善された。 やや有効:肌のはり、つやがやや改善された。 無 効:使用前と変化なし。 上記各評価結果を表7に示す。<Beautiful Skin Effect> (Evaluation) (Contents) Effective: Dullness of the skin is not noticeable. Somewhat effective: The dullness of the skin became less noticeable. Ineffective: No change from before use. <Effect of preventing skin aging> (Evaluation) (Details) Effective: The skin's elasticity and gloss were improved. Slightly effective: The skin's elasticity and gloss were slightly improved. Ineffective: No change from before use. Table 7 shows the evaluation results.

【0047】[0047]

【表7】 [Table 7]

【0048】上記評価結果から明らかなように、本発明
に係わるクリームは、抗酸化能を有し、美肌効果及び皮
膚老化防止効果に優れたものであった。
As is clear from the above evaluation results, the cream according to the present invention has antioxidative ability and is excellent in the skin beautifying effect and the skin aging preventing effect.

【0049】[0049]

【発明の効果】以上述べたように、本発明の皮膚外用剤
は、特定の構成より成るリポソーム含有水分散液と各種
薬剤とを配合することにより、各々の薬剤の持つ効果を
著しく向上させ、美容及び医療において極めて有用なも
のである。
As described above, the external preparation for skin of the present invention contains a liposome-containing aqueous dispersion having a specific composition and various drugs to remarkably improve the effect of each drug. It is extremely useful in beauty and medicine.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/00 X ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI technical display area A61K 7/00 X

Claims (9)

【特許請求の範囲】[Claims] 【請求項1】下記の成分(a)、(b)及び(c); (a)リン脂質 0.1〜5重量% (b)コレステロール及び/又はその誘導体 0.1〜5重量% (c)グリセリン及び/又は1,3−ブチレングリコール 5〜40重量% を含有し、かつ、(a):(b)が1:0.1〜1:1
であるリポソーム含有水分散液と、ヒアルロン酸、コラ
ーゲン、エラスチンから選ばれる1種又は2種以上の保
湿剤とを含有することを特徴とする皮膚外用剤。
1. The following components (a), (b) and (c); (a) phospholipid 0.1 to 5% by weight (b) cholesterol and / or its derivative 0.1 to 5% by weight (c ) Glycerin and / or 1,3-butylene glycol is contained in an amount of 5 to 40% by weight, and (a) :( b) is 1: 0.1 to 1: 1.
An external preparation for skin comprising the liposome-containing aqueous dispersion, which is, and one or more moisturizers selected from hyaluronic acid, collagen, and elastin.
【請求項2】リン脂質が、水素添加卵黄リン脂質、水素
添加大豆リン脂質、水素添加ホスファチジルコリン、水
素添加ホスファチジルセリンから選ばれる一種又は二種
以上であることを特徴とする請求項1記載の皮膚外用
剤。
2. The skin according to claim 1, wherein the phospholipid is one or more selected from hydrogenated egg yolk phospholipid, hydrogenated soybean phospholipid, hydrogenated phosphatidylcholine and hydrogenated phosphatidylserine. Topical agent.
【請求項3】請求項1記載の保湿剤の含有量が0.00
1〜5重量%であることを特徴とする請求項1又は2の
いずれかに記載の皮膚外用剤。
3. The content of the moisturizer according to claim 1 is 0.00.
The external preparation for skin according to claim 1, which is 1 to 5% by weight.
【請求項4】下記の成分(a)、(b)及び(c); (a)リン脂質 0.1〜5重量% (b)コレステロール及び/又はその誘導体 0.1〜5重量% (c)グリセリン及び/又は1,3−ブチレングリコール 5〜40重量% を含有し、かつ、(a):(b)が1:0.1〜1:1
であるリポソーム含有水分散液と、プラセンタエキス、
アスコルビン酸及びその誘導体から選ばれる1種又は2
種以上の美白剤とを含有することを特徴とする皮膚外用
剤。
4. The following components (a), (b) and (c): (a) Phospholipid 0.1 to 5% by weight (b) Cholesterol and / or its derivative 0.1 to 5% by weight (c ) Glycerin and / or 1,3-butylene glycol is contained in an amount of 5 to 40% by weight, and (a) :( b) is 1: 0.1 to 1: 1.
An aqueous dispersion containing liposomes, which is a placenta extract,
One or two selected from ascorbic acid and its derivatives
A skin external preparation characterized by containing at least one kind of whitening agent.
【請求項5】リン脂質が、水素添加卵黄リン脂質、水素
添加大豆リン脂質、水素添加ホスファチジルコリン、水
素添加ホスファチジルセリンから選ばれる一種又は二種
以上であることを特徴とする請求項4記載の皮膚外用
剤。
5. The skin according to claim 4, wherein the phospholipid is one or more selected from hydrogenated egg yolk phospholipid, hydrogenated soybean phospholipid, hydrogenated phosphatidylcholine and hydrogenated phosphatidylserine. Topical agent.
【請求項6】請求項4記載の美白剤の含有量が0.00
1〜5重量%であることを特徴とする請求項4又は5の
いずれかに記載の皮膚外用剤。
6. The content of the whitening agent according to claim 4 is 0.00.
The external preparation for skin according to claim 4, which is 1 to 5% by weight.
【請求項7】下記の成分(a)、(b)及び(c); (a)リン脂質 0.1〜5重量% (b)コレステロール及び/又はその誘導体 0.1〜5重量% (c)グリセリン及び/又は1,3−ブチレングリコール 5〜40重量% を含有し、かつ、(a):(b)が1:0.1〜1:1
であるリポソーム含有水分散液と、ラクトフェリン、麦
芽根抽出物、モッカ抽出物から選ばれる1種又は2種以
上の抗酸化剤とを含有することを特徴とする皮膚外用
剤。
7. The following components (a), (b) and (c); (a) phospholipid 0.1 to 5% by weight (b) cholesterol and / or its derivative 0.1 to 5% by weight (c ) Glycerin and / or 1,3-butylene glycol is contained in an amount of 5 to 40% by weight, and (a) :( b) is 1: 0.1 to 1: 1.
The external preparation for skin comprising the liposome-containing aqueous dispersion which is 1. and one or more antioxidants selected from lactoferrin, malt root extract, and mocca extract.
【請求項8】リン脂質が、水素添加卵黄リン脂質、水素
添加大豆リン脂質、水素添加ホスファチジルコリン、水
素添加ホスファチジルセリンから選ばれる一種又は二種
以上であることを特徴とする請求項7記載の皮膚外用
剤。
8. The skin according to claim 7, wherein the phospholipid is one or more selected from hydrogenated egg yolk phospholipid, hydrogenated soybean phospholipid, hydrogenated phosphatidylcholine and hydrogenated phosphatidylserine. Topical agent.
【請求項9】請求項7記載の抗酸化剤の含有量が乾燥固
形分として0.0001〜5重量%であることを特徴と
する請求項7又は8のいずれかに記載の皮膚外用剤。
9. The external preparation for skin according to claim 7, wherein the content of the antioxidant according to claim 7 is 0.0001 to 5% by weight as a dry solid content.
JP33944894A 1994-12-28 1994-12-28 External preparation for skin Expired - Lifetime JP3521517B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP33944894A JP3521517B2 (en) 1994-12-28 1994-12-28 External preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33944894A JP3521517B2 (en) 1994-12-28 1994-12-28 External preparation for skin

Publications (2)

Publication Number Publication Date
JPH08183726A true JPH08183726A (en) 1996-07-16
JP3521517B2 JP3521517B2 (en) 2004-04-19

Family

ID=18327565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP33944894A Expired - Lifetime JP3521517B2 (en) 1994-12-28 1994-12-28 External preparation for skin

Country Status (1)

Country Link
JP (1) JP3521517B2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013436A1 (en) * 1995-03-23 1998-04-02 The Nisshin Oil Mills, Ltd. Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition
EP1092423A2 (en) * 1999-10-13 2001-04-18 L'oreal Use of DHEA or its precursors and metabolites as skin depigmentation agents
US6416771B1 (en) 1995-03-23 2002-07-09 The Nisshin Oil Mills Ltd. Moisturizing composition, base containing the same, and cosmetic or external preparation containing the moisturizing composition
JP2010024180A (en) * 2008-07-18 2010-02-04 Mikimoto Pharmaceut Co Ltd Oil-in-water emulsion composition for promoting recovery of skin barrier function
JP2010196048A (en) * 2009-01-30 2010-09-09 Kose Corp Novel water-soluble polymer, and cosmetic material or skin preparation for external use containing the same
JP2010254974A (en) * 2009-03-31 2010-11-11 Kose Corp Water-soluble copolymer and cosmetic or external preparation for skin obtained by blending the same
JP2011079745A (en) * 2009-10-02 2011-04-21 Face:Kk Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same
US10426715B2 (en) 2015-03-27 2019-10-01 Kose Corporation Liposome composition
CN113115833A (en) * 2019-12-31 2021-07-16 丰益(上海)生物技术研发中心有限公司 Thick soup and preparation process thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009110205A1 (en) 2008-03-04 2009-09-11 ナガセケムテックス株式会社 Agent for increasing the quantity of hyaluronic acid

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013436A1 (en) * 1995-03-23 1998-04-02 The Nisshin Oil Mills, Ltd. Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition
US6117434A (en) * 1995-03-23 2000-09-12 The Nisshin Oil Mills Ltd. Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition
US6416771B1 (en) 1995-03-23 2002-07-09 The Nisshin Oil Mills Ltd. Moisturizing composition, base containing the same, and cosmetic or external preparation containing the moisturizing composition
EP1092423A2 (en) * 1999-10-13 2001-04-18 L'oreal Use of DHEA or its precursors and metabolites as skin depigmentation agents
EP1092423B1 (en) * 1999-10-13 2009-05-13 L'oreal Use of DHEA or its precursors and metabolites as skin depigmentation agents
JP2010024180A (en) * 2008-07-18 2010-02-04 Mikimoto Pharmaceut Co Ltd Oil-in-water emulsion composition for promoting recovery of skin barrier function
JP2010196048A (en) * 2009-01-30 2010-09-09 Kose Corp Novel water-soluble polymer, and cosmetic material or skin preparation for external use containing the same
JP2010254974A (en) * 2009-03-31 2010-11-11 Kose Corp Water-soluble copolymer and cosmetic or external preparation for skin obtained by blending the same
JP2011079745A (en) * 2009-10-02 2011-04-21 Face:Kk Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same
US10426715B2 (en) 2015-03-27 2019-10-01 Kose Corporation Liposome composition
CN113115833A (en) * 2019-12-31 2021-07-16 丰益(上海)生物技术研发中心有限公司 Thick soup and preparation process thereof
CN113115833B (en) * 2019-12-31 2024-08-06 丰益(上海)生物技术研发中心有限公司 Thick soup and preparation process thereof

Also Published As

Publication number Publication date
JP3521517B2 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
JP2544198B2 (en) Composition based on a hydratable lamellar phase or liposome consisting of an extract of mulberry and a pharmaceutical composition, in particular a dermatological composition with skin lightening or anti-inflammatory activity, or a cosmetic composition Stuff
EP0616799A1 (en) Cosmetic delivery system for salicylic acid and process for preparation of same
JP2003081737A (en) Cosmetic with triply stabilized retinol
JPH09143063A (en) Composition suitable for external use
JPS63275506A (en) Skin cosmetic
KR20100052457A (en) Vesicle composition and external preparation for skin
JPH07277939A (en) Skin external preparation
JPH08183726A (en) Skin preparation for external use
JPH08283139A (en) Dermal preparation for external use
JP2012051872A (en) Skin cosmetic
JP2005179313A (en) Method for producing base agent for skin cosmetic, and skin cosmetic
JPS61260008A (en) Cosmetic composition
JP5000033B2 (en) Advanced hydrogenated lecithin
JP2694756B2 (en) Cosmetics containing divalent and trivalent iron salts
JP3527053B2 (en) Cosmetics
JPS6256411A (en) Beautifying agent
KR20220027633A (en) Cosmetic Composition Containing LHA Crystal Pearl Effective For Improving Skin Trouble
JP3441387B2 (en) Moisturizer, skin cosmetics and bath additives
JP6790710B2 (en) Ursolic acid-containing liposome dispersion
JP2004051561A (en) Skin cosmetic composition
JP2000001416A (en) Polyol-containing liposome
JPH041115A (en) Dermal drug for external use
JPS61254510A (en) External agent for skin
JPH0570333A (en) Skin medicine for external use
JP2000044456A (en) Dermal pretreatment agent

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040202

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150220

Year of fee payment: 11

EXPY Cancellation because of completion of term